Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. BioXcel Therapeutics's shares outstanding for the quarter that ended in Mar. 2026 was 27.08 Mil.
BioXcel Therapeutics's quarterly shares outstanding
increased
from Dec. 2025 (22.33 Mil) to Mar. 2026 (27.08 Mil).
It means BioXcel Therapeuticsissued new shares from Dec. 2025 to Mar. 2026 .
BioXcel Therapeutics's annual shares outstanding
increased
from Dec. 2024 (3.10 Mil) to Dec. 2025 (22.33 Mil).
It means BioXcel Therapeuticsissued new shares from Dec. 2024 to Dec. 2025 .
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
BioXcel Therapeutics Shares Outstanding (EOP) Related Terms
BioXcel Therapeutics Shares Outstanding (EOP) Historical Data
* Premium members only.
The historical data trend for BioXcel Therapeutics's Shares Outstanding (EOP) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:BX20 vs IXHL, SCYX, INIS: Shares Outstanding (EOP) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, BioXcel Therapeutics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioXcel Therapeutics Shares Outstanding (EOP) vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioXcel Therapeutics's Shares Outstanding (EOP) distribution charts can be found below:
* The bar in red indicates where BioXcel Therapeutics's Shares Outstanding (EOP) falls into.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
What does a Shares Outstanding (EOP) of 27.08 Mil mean?
BioXcel Therapeutics (FRA:BX20) has a Shares Outstanding (EOP) of 27.08 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on BioXcel Therapeutics and its competitors.
Is BioXcel Therapeutics' Shares Outstanding (EOP) too high?
BioXcel Therapeutics' current Shares Outstanding (EOP) is 27.08 Mil. Overall, BioXcel Therapeutics has a GF Score™ of 19/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioXcel Therapeutics' Shares Outstanding (EOP) compare to IXHL and SCYX?
BioXcel Therapeutics' Shares Outstanding (EOP) of 27.08 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Drug Manufacturers company?
A good Shares Outstanding (EOP) depends on the Drug Manufacturers industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on BioXcel Therapeutics and its competitors. BioXcel Therapeutics's current Shares Outstanding (EOP) is 27.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioXcel Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, BioXcel Therapeutics (FRA:BX20) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.54, compared to a current price of €0.72 — trading 33.3% above its estimated fair value. The current Shares Outstanding (EOP) is 27.08 Mil. BioXcel Therapeutics' overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For BioXcel Therapeutics (FRA:BX20), the current Shares Outstanding (EOP) is 27.08 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioXcel Therapeutics (FRA:BX20) Overvalued in 2026?
Based on GuruFocus' analysis, BioXcel Therapeutics stock appears to be overvalued.
The current stock price of €0.72 is trading 33.3% above its estimated GF Value™ of €0.54.
GuruFocus considers BioXcel Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:BX20:
Shares Outstanding (EOP): 27.08 Mil
GF Value™: €0.54 vs. price of €0.72 (33.3% above fair value)
No single metric tells the full story. See the FRA:BX20 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
19GF Score
Get the complete analysis for FRA:BX20
Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BX20 has been successfully added to your 
